Skip to main content
Top
Published in: Clinical & Experimental Metastasis 3/2009

01-03-2009 | Research Paper

Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature

Authors: Lucia Martiniova, Edwin W. Lai, Abdel G. Elkahloun, Mones Abu-Asab, Andrea Wickremasinghe, Daniel C. Solis, Shiromi M. Perera, Thanh-Truc Huynh, Irina A. Lubensky, Arthur S. Tischler, Richard Kvetnansky, Salvatore Alesci, John C. Morris, Karel Pacak

Published in: Clinical & Experimental Metastasis | Issue 3/2009

Login to get access

Abstract

Pheochromocytomas are chromaffin cell-derived neuroendocrine tumors. There is presently no cure for metastatic pheochromocytoma and no reliable way to distinguish malignant from benign tumors before the development of metastases. In order to successfully manage pheochromocytoma, it is necessary to better understand the biological determinants of tumor behavior. For this purpose, we have recently established a mouse model of metastatic pheochromocytoma using tail vein injection of mouse pheochromocytoma (MPC) cells. We optimized this model modifying the number of cells injected, length of trypsin pre-treatment, and incubation temperature and duration for the MPC cells before injection, and by serial passage and re-selection of tumors exhibiting the metastatic phenotype. We evaluated the effect of these modifications on tumor growth using serial in vivo Magnetic Resonance Imaging studies. These results show that number of cells injected, the pre-injection incubation temperature, and duration of trypsin treatment are important factors to produce faster growing, more aggressive tumors that yielded secondary metastatic lesions. Serial harvest, culture and re-selection of metastatic liver lesions produced even more aggressive pheochromocytoma cells that retained their biochemical phenotype. Microarray gene expression comparison and quantitative real-time PCR of these more aggressive cells to the MPC-parental cell line identified genes that may be important for the metastatic process.
Literature
1.
go back to reference Lack EE (1997) Tumors of the adrenal gland and extra-adrenal paraganglia. Atlas of human pathology. Armed Forces Institute of Pathology, Washington Lack EE (1997) Tumors of the adrenal gland and extra-adrenal paraganglia. Atlas of human pathology. Armed Forces Institute of Pathology, Washington
5.
go back to reference Ohta S, Lai EW, Morris JC et al (2008) Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells. Mol Carcinog 47:245–251. doi:10.1002/mc.20388 PubMedCrossRef Ohta S, Lai EW, Morris JC et al (2008) Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells. Mol Carcinog 47:245–251. doi:10.​1002/​mc.​20388 PubMedCrossRef
7.
8.
go back to reference Martiniova L, Kotys S, Thomasson D, et al (2008) Non-invasive monitoring of a murine model of metastatic pheochromocytoma: a comparison of contrast enhanced microCT and non-enhanced MRI. J Magn Reson Imaging (accepted) Martiniova L, Kotys S, Thomasson D, et al (2008) Non-invasive monitoring of a murine model of metastatic pheochromocytoma: a comparison of contrast enhanced microCT and non-enhanced MRI. J Magn Reson Imaging (accepted)
9.
10.
go back to reference Alesci S, Perera SM, Lai EW et al (2007) Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: potential clinical and therapeutic relevance. Endocrinology 148:3900–3907. doi:10.1210/en.2007-0521 PubMedCrossRef Alesci S, Perera SM, Lai EW et al (2007) Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: potential clinical and therapeutic relevance. Endocrinology 148:3900–3907. doi:10.​1210/​en.​2007-0521 PubMedCrossRef
11.
go back to reference Eisenhofer G, Walther MM, Huynh TT et al (2001) Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocr Metab 86:1999–2008. doi:10.1210/jc.86.5.1999 PubMedCrossRef Eisenhofer G, Walther MM, Huynh TT et al (2001) Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocr Metab 86:1999–2008. doi:10.​1210/​jc.​86.​5.​1999 PubMedCrossRef
13.
go back to reference Brown JL, Snir M, Noushmehr H et al (2008) Transcriptional profiling of endogenous germ layer precursor cells identifies dusp4 as an essential gene in zebrafish endoderm specification. Proc Natl Acad Sci USA 105:12337–12342. doi:10.1073/pnas.0805589105 PubMedCrossRef Brown JL, Snir M, Noushmehr H et al (2008) Transcriptional profiling of endogenous germ layer precursor cells identifies dusp4 as an essential gene in zebrafish endoderm specification. Proc Natl Acad Sci USA 105:12337–12342. doi:10.​1073/​pnas.​0805589105 PubMedCrossRef
15.
go back to reference Tischler AS, Powers JF, Alroy J (2004) Animal models of pheochromocytoma. Histol Histopathol 19:883–895PubMed Tischler AS, Powers JF, Alroy J (2004) Animal models of pheochromocytoma. Histol Histopathol 19:883–895PubMed
Metadata
Title
Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature
Authors
Lucia Martiniova
Edwin W. Lai
Abdel G. Elkahloun
Mones Abu-Asab
Andrea Wickremasinghe
Daniel C. Solis
Shiromi M. Perera
Thanh-Truc Huynh
Irina A. Lubensky
Arthur S. Tischler
Richard Kvetnansky
Salvatore Alesci
John C. Morris
Karel Pacak
Publication date
01-03-2009
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 3/2009
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-009-9236-0

Other articles of this Issue 3/2009

Clinical & Experimental Metastasis 3/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine